Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03822494 · ClinicalTrials.gov registry record · NA

CyberKnife Dose Escalation Prostate Cancer Trial

A NA study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Crozer-Keystone Health System.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT03822494 is a NA study of Prostate Cancer and Prostate Adenocarcinoma that is active but no longer recruiting, run by Crozer-Keystone Health System. The registered enrollment target is 100 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03822494, a NA study of Prostate Cancer and Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Crozer-Keystone Health System.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.

Interventions

  • RADIATION CyberKnife SBRT

Study Locations (1)

Pennsylvania

  • Philadelphia CyberKnife - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-07-12
Est. Completion 2028-07-12
Phase NA

Sponsor

Crozer-Keystone Health System

2 total trials

What the Registry Record Tells You About NCT03822494

The ClinicalTrials.gov registry entry for NCT03822494 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Crozer-Keystone Health System, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which CyberKnife SBRT is the first listed.

NCT03822494 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03822494 about?

NCT03822494 is a clinical study titled "CyberKnife Dose Escalation Prostate Cancer Trial". Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convinci...

What is the current status of trial NCT03822494?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-07-12. Estimated completion is 2028-07-12.

What conditions does trial NCT03822494 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm.

What interventions are being tested in trial NCT03822494?

The interventions under investigation include: CyberKnife SBRT (RADIATION).

Who is sponsoring clinical trial NCT03822494?

This trial is sponsored by Crozer-Keystone Health System, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03822494 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.